Real-life data of immune recovery using bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48–96 weeks of RETROBIC Study
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Jesús Troya und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Hospital Universitario Infanta Leonor, Madrid, Spain. Hauptthemen laut MEDLINE: HIV Infections, Piperazines, Pyridones, Alanine. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Background
Switching strategy with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) has become a gold standard for people living with HIV (PLWH), achieving high efficacy and safety rates. However, data regarding immune status in long-term real-life cohorts of pretreated patients are needed.
Methods
We performed a multicentre, non-controlled, retrospective study in virologically suppressed PLWH switching to B/F/TAF. We evaluated CD4+, CD8+ and CD4+/CD8+ ratio, efficacy and safety at weeks 48 and 96.
Results
The study comprised 1966 PLWH from 12 hospitals in Spain, of whom 80% were men, and the median age was 51.0 [42.0–57.0] years. The median time of HIV infection was 18.0 [10.0–27.0] years. No significant changes in CD4+, CD8+ T cells, or CD4+/CD8+ were observed after 96 weeks. Nevertheless, in women at weeks 48 and 96, we found a significant increase of CD4+ T cells and a significant decrease in CD8+ T cells. In patients ≥60 years at week 96, CD4 T cells significantly increased and CD8+ T cells significantly decreased at week 48. The on-treatment analysis revealed HIV-RNA <50 copies/mL in 95.6% (1700/1779) and 96.7% (1312/1356) of patients at weeks 48 and 96, respectively. The rates increased to 99.2% (1765/1779) and 99.7% (1352/1356) when considering HIV-RNA <200 copies/mL. No resistance mutations were detected in virologic failures. B/F/TAF discontinuations accounted for 10.2% (200). Simplification was the most common reason for discontinuation in 3.8% (74) of patients.
Conclusion
In long-term virologically controlled PLWH, B/F/TAF achieved high efficacy rates and slightly improved immune status in women and individuals aged 60 and over after 48 and 96 of switching.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Hospital Universitario Infanta Leonor, Madrid, Spain.
- Department of Infectious Diseases, Hospital Álvaro Cunqueiro, Vigo, Spain.
- Department of Infectious Diseases, Hospital Universitario La Paz, Madrid, Spain.
- Department of Infectious Diseases, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
- Department of Infectious Diseases, Hospital Príncipe de Asturias, Alcalá de Henares, Spain.
- Department of Infectious Diseases, Hospital Universitario La Princesa, Madrid, Spain.
ORCID-Profile: Jesús Troya, Luis Buzón
Zitieren
APA
Troya, J., Pousada, G., Micán, R., Galera, C., Sanz, J., de Los Santos, I., Dueñas, C., Cabello, N., Martín, C., Galindo, M. J., Garcinuño, M. Á., Pedrero-Tomé, R., & Buzón, L. (2024). Real-life data of immune recovery using bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48–96 weeks of RETROBIC Study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae011
Vancouver
Troya J, Pousada G, Micán R, Galera C, Sanz J, de Los Santos I, et al. Real-life data of immune recovery using bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48–96 weeks of RETROBIC Study. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae011
BibTeX
@article{Troya2024,
author = {Troya, Jesús and Pousada, Guillermo and Micán, Rafael and Galera, Carlos and Sanz, José and de Los Santos, Ignacio and Dueñas, Carlos and Cabello, Noemí and Martín, Cristina and Galindo, María Josefa and Garcinuño, María Ángeles and Pedrero-Tomé, Roberto and Buzón, Luis},
title = {Real-life data of immune recovery using bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48–96 weeks of RETROBIC Study},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae011}
}
EUVIMED